CR10208A - Inhibidores de quinasa basados en la hidantoina - Google Patents
Inhibidores de quinasa basados en la hidantoinaInfo
- Publication number
- CR10208A CR10208A CR10208A CR10208A CR10208A CR 10208 A CR10208 A CR 10208A CR 10208 A CR10208 A CR 10208A CR 10208 A CR10208 A CR 10208A CR 10208 A CR10208 A CR 10208A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- hydantoin
- useful
- methods
- quinase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula a comoposiciones farmacéuticas que contienen dichos compuestos, a métodos para su obtención y métodos para su utilización. Estos compuestos son útiles para tratar enfermedades caracterizadas por la hiperactividad de la MEK. Por consiguiente, estos compuestos son útiles para el tratamiento de enfermedades tales como el cáncer, trastornos cognitivos y del SNC y enfermedades inflamatorias y autoinmunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77565806P | 2006-02-22 | 2006-02-22 | |
US86110506P | 2006-11-27 | 2006-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10208A true CR10208A (es) | 2008-09-22 |
Family
ID=37891469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10208A CR10208A (es) | 2006-02-22 | 2008-08-14 | Inhibidores de quinasa basados en la hidantoina |
Country Status (18)
Country | Link |
---|---|
US (1) | US7612212B2 (es) |
EP (1) | EP1989186B1 (es) |
JP (1) | JP2009527521A (es) |
KR (1) | KR101060981B1 (es) |
AR (1) | AR059590A1 (es) |
AT (1) | ATE488505T1 (es) |
AU (1) | AU2007217611B2 (es) |
BR (1) | BRPI0708182A2 (es) |
CA (1) | CA2642794A1 (es) |
CR (1) | CR10208A (es) |
DE (1) | DE602007010592D1 (es) |
EC (1) | ECSP088693A (es) |
IL (1) | IL193482A (es) |
MA (1) | MA30232B1 (es) |
NO (1) | NO20083690L (es) |
RU (1) | RU2008137526A (es) |
TW (1) | TW200804299A (es) |
WO (1) | WO2007096259A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008101840A1 (en) * | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
WO2009021887A1 (en) * | 2007-08-16 | 2009-02-19 | F. Hoffmann-La Roche Ag | Substituted hydantoins |
FR2920774B1 (fr) * | 2007-09-06 | 2009-10-30 | Galderma Res & Dev | Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant |
KR20100086503A (ko) | 2007-12-20 | 2010-07-30 | 에프. 호프만-라 로슈 아게 | Mek 키나아제 저해제로서의 치환된 히단토인 |
US8530457B2 (en) * | 2008-05-20 | 2013-09-10 | Fox Chase Cancer Center | Method for the treatment of lymphangioleiomyomatosis (LAM) |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
DK2959900T3 (en) | 2008-06-16 | 2017-06-26 | Univ Tennessee Res Found | CONNECTION TO TREATMENT OF CANCER |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
FR2946342B1 (fr) * | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux derives de dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946340B1 (fr) * | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946341B1 (fr) * | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946345B1 (fr) | 2009-06-05 | 2011-05-20 | Galderma Res & Dev | Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
EP3028699B1 (en) | 2010-02-25 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
ES2714875T3 (es) | 2010-03-09 | 2019-05-30 | Dana Farber Cancer Inst Inc | Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer |
TW201840336A (zh) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
AU2013337702A1 (en) | 2012-11-02 | 2015-05-21 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor |
WO2014133071A1 (ja) | 2013-02-27 | 2014-09-04 | 第一三共株式会社 | Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法 |
CN109568312A (zh) * | 2013-03-05 | 2019-04-05 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
JP6403172B2 (ja) | 2013-10-25 | 2018-10-10 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. | ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用 |
CN106573060A (zh) | 2014-07-15 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物 |
MX2019015431A (es) | 2017-06-23 | 2021-03-30 | Cstone Pharmaceuticals | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. |
CN114478447A (zh) * | 2020-11-13 | 2022-05-13 | 江苏恒瑞医药股份有限公司 | 苯并含氧环类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3434680A1 (de) * | 1984-09-21 | 1986-04-03 | Cassella Ag, 6000 Frankfurt | 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung |
ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
KR19990012061A (ko) | 1997-07-26 | 1999-02-25 | 성재갑 | 파네실 전이효소 저해제로 유용한 하이덴토인 유도체 |
DK1280801T3 (da) | 2000-05-03 | 2006-01-23 | Hoffmann La Roche | Hydantoinholdige glucokinaseaktivatorer |
GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
MX2007001846A (es) | 2004-08-17 | 2007-03-28 | Hoffmann La Roche | Hidantoinas sustituidas. |
TW200621766A (en) | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
-
2007
- 2007-01-25 US US11/657,800 patent/US7612212B2/en not_active Expired - Fee Related
- 2007-02-12 AT AT07726336T patent/ATE488505T1/de not_active IP Right Cessation
- 2007-02-12 WO PCT/EP2007/051313 patent/WO2007096259A1/en active Application Filing
- 2007-02-12 AU AU2007217611A patent/AU2007217611B2/en not_active Expired - Fee Related
- 2007-02-12 JP JP2008555743A patent/JP2009527521A/ja active Pending
- 2007-02-12 BR BRPI0708182-0A patent/BRPI0708182A2/pt not_active IP Right Cessation
- 2007-02-12 KR KR1020087020701A patent/KR101060981B1/ko not_active IP Right Cessation
- 2007-02-12 RU RU2008137526/04A patent/RU2008137526A/ru not_active Application Discontinuation
- 2007-02-12 DE DE602007010592T patent/DE602007010592D1/de active Active
- 2007-02-12 CA CA002642794A patent/CA2642794A1/en not_active Abandoned
- 2007-02-12 EP EP07726336A patent/EP1989186B1/en active Active
- 2007-02-16 TW TW096105927A patent/TW200804299A/zh unknown
- 2007-02-20 AR ARP070100715A patent/AR059590A1/es unknown
-
2008
- 2008-08-14 IL IL193482A patent/IL193482A/en not_active IP Right Cessation
- 2008-08-14 CR CR10208A patent/CR10208A/es not_active Application Discontinuation
- 2008-08-21 EC EC2008008693A patent/ECSP088693A/es unknown
- 2008-08-27 NO NO20083690A patent/NO20083690L/no not_active Application Discontinuation
- 2008-08-27 MA MA31198A patent/MA30232B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
IL193482A0 (en) | 2009-05-04 |
IL193482A (en) | 2012-01-31 |
EP1989186B1 (en) | 2010-11-17 |
BRPI0708182A2 (pt) | 2011-05-17 |
AU2007217611A1 (en) | 2007-08-30 |
ECSP088693A (es) | 2008-09-29 |
CA2642794A1 (en) | 2007-08-30 |
EP1989186A1 (en) | 2008-11-12 |
WO2007096259A1 (en) | 2007-08-30 |
TW200804299A (en) | 2008-01-16 |
AU2007217611B2 (en) | 2012-08-23 |
KR101060981B1 (ko) | 2011-08-31 |
US20070197617A1 (en) | 2007-08-23 |
KR20080091491A (ko) | 2008-10-13 |
MA30232B1 (fr) | 2009-02-02 |
JP2009527521A (ja) | 2009-07-30 |
RU2008137526A (ru) | 2010-03-27 |
AR059590A1 (es) | 2008-04-16 |
DE602007010592D1 (de) | 2010-12-30 |
ATE488505T1 (de) | 2010-12-15 |
NO20083690L (no) | 2008-09-18 |
US7612212B2 (en) | 2009-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10208A (es) | Inhibidores de quinasa basados en la hidantoina | |
CO2017009298A2 (es) | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 | |
CL2018000150A1 (es) | Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508) | |
BRPI0515371A (pt) | hidantoìnas substituìdas | |
CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
CO2022004694A2 (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
CR20150255A (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
CO6710897A2 (es) | Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer | |
CR20130308A (es) | Compuestos y su uso como inhibidores de bace | |
CU20110168A7 (es) | Derivados de benzofuranilo | |
MY184882A (en) | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors | |
ECSP10010475A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
EA201290305A1 (ru) | Производные трициклического пиразоламина | |
PA8848201A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
CR20110255A (es) | Nuevos compuestos 578 | |
BR112013005141A2 (pt) | diazetidinil diamida como inibidores de monoacilglicerol lipase | |
ECSP12012218A (es) | Derivados de piperidin-4-il azetidina como inhibidores de jak1 | |
CO2017006174A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis | |
CO6511283A2 (es) | Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer | |
BR112012010253A2 (pt) | compostos de pirimidina como moduladores do receptor delta opioide | |
UY33910A (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC | |
EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
CO6721019A2 (es) | Quinazolincarboxamida azetidinas | |
UY31065A1 (es) | Heterociclos ciclicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |